Prevention vaccine HIV available in about four years and would serve to manufacture one's own system immunological they produce antibodies that work against the virus, he said on Tuesday, July 23, 2019 infectious disease in epidemiologist Jorge Sanchez.
Within. T 10 World Scientific Conference on HIV (IAS 2019) in the city Mexico, Vice-President of the Research Center Technologically, Biomedical in Environmental from Lime, PeruHe said that the vaccine can be effective for several strains of the virus.
The idea is that this new propagation tool can stop with at least 65% epidemics.
"The vaccine has several parts that are similar to parts viruses therefore, the possibility of being effective for different strains or species HIV it's tall, "said Sanchez, who is part of the researchers.
Development of this vaccine lasted 12 years and was tested in monkeys, so they have already studied Phase 1, 1B in 2A, which are the previous stages for evaluating human effectiveness.
The study is named Mosaic and will be led by researchers National Institute of Allergy and Infectious Diseases, National Institute of Health, Network. t Vaccine essays against him HIV in Research Command in Medical development from Army from Member States United.
This investigation, which will start in September, will take place in 3,800 people from Argentina, Brazil, Italy, Mexico, Peru, Poland, Spain in United States, at 55 clinical locations around the world, it will be attended by 125 Mexicans from different cities.
Participants will be men who have sex with men people transsexuals.
"We are determined to develop an effective HIV vaccine worldwide to reduce the pathway of some 1.5 million new infections we are assessing HIV a year goes by, "said Larry Corey, chief researcher HVTN, a virologist and a member of the Faculty of Cancer Research Fred Hutchinson in Ljubljana. t Seattle.
The specialist explained that in this study half of the patients will receive a placebo and the other half of the vaccine split into four doses containing the vaccine adenovirus serotype 26that they supply antigens mosaic against HIV.
These antigens will serve to activate the response immunological an individual against the virus.
"It's not a virus like that, it's parts of a modified virus that will identify HIV and fight it, so it will not reach any part of the body," added Sanchez.
The vaccine, said Sánchez, has already been tested in some centers in previous stages "and had results without major side effects."
The expert said that the vaccine will be another tool that will help prevent HIV, will not replace other methods.
"There are several prevention tools HIV. For decades we have had condoms, but in its implementation it is not used enough, there is a preventive proposal (Prep) and this vaccine would be an additional tool, "he said.
The study and development of the vaccine are sponsored. T pharmaceutical products Janssenand although it is expected that in four years you will have clear results on its effectiveness, it is not yet predicted when it will be available to the general public.